8.3 Central PN Macronutrient Formulation

8.3 Central PN Macronutrient Formulation

Clinical Core: Central parenteral nutrition requires rigorous, individualized formulation of macronutrient substrates—carbohydrates, amino acids, and lipids. Understanding substrate caloric densities, specialized amino acid kinetics, lipid generation profiles, essential fatty acid physiology, and glucose oxidation ceilings is fundamental to avoiding overfeeding toxicities such as hepatic steatosis, hypercapnic respiratory failure, and essential fatty acid deficiency.

Macronutrient Substrates and Caloric Densities

Parenteral macronutrients possess distinct biochemical structures and caloric densities that differ from their enteral counterparts:

PARENTERAL MACRONUTRIENT SUBSTRATES

1. DEXTROSE MONOHYDRATE ----> 3.4 kcal/g  (Hydrated C6H12O6 · H2O, MW 198.17)
2. CRYSTALLINE AMINO ACIDS -> 4.0 kcal/g  (16% Nitrogen: Protein / 6.25 = N)
3. INTRAVENOUS LIPID (IVLE) -> 10% = 1.1 kcal/mL | 20% = 2.0 kcal/mL | 30% = 3.0 kcal/mL

1. Dextrose Monohydrate (Carbohydrate)

• Biochemical Structure: In enteral nutrition, dietary starch and anhydrous glucose yield $4.0\text{ kcal/g}$. In parenteral solutions, dextrose is commercially prepared as dextrose monohydrate ($C_6H_{12}O_6 \cdot H_2O$, molecular weight 198.17), containing one molecule of water of crystallization. Because this water molecule adds molecular mass without contributing metabolic energy, parenteral dextrose yields exactly $3.4\text{ kcal per gram}$.
• Available Stock Concentrations:
  • $D_{10}W$ ($10\% = 100\text{ g/L}$)
  • $D_{50}W$ ($50\% = 500\text{ g/L}$)
  • $D_{70}W$ ($70\% = 700\text{ g/L}$)
• Minimum Carbohydrate Requirement: An adult requires a minimum of $100\text{ to } 150\text{ g/day}$ (approximately $2\text{ g/kg/day}$) of carbohydrate to:
  1. Meet the obligate glucose requirements of the human brain ($100\text{--}120\text{ g/day}$), erythrocytes, renal medulla, and healing wounds.
  2. Suppress hepatic gluconeogenesis, preventing rapid endogenous skeletal muscle proteolysis.
  3. Suppress hepatic ketogenesis, preventing starvation ketoacidosis.

2. Crystalline Amino Acids (Protein)

• Energy Density & Nitrogen Kinetics: Crystalline amino acids yield $4.0\text{ kcal/g}$. Nitrogen accounts for approximately $16\%$ of amino acid mass by weight, establishing the fundamental nitrogen conversion:

$\text{Nitrogen (g)} = \frac{\text{Amino Acids (g)}}{6.25}$

• Stock Concentrations: Standard parenteral amino acid solutions are available in concentrations of $10\%$ ($100\text{ g/L}$), $15\%$ ($150\text{ g/L}$), and $20\%$ ($200\text{ g/L}$).
• Formulation Profiles:
  • Standard Formulations: Balanced mixtures of essential and non-essential amino acids modeled after high-biological-value egg and milk proteins (e.g., Aminosyn, Travasol, Plenamine). Suitable for $\ge 95\%$ of hospitalized adults.
  • Hepatic Formulations (HepatAmine): Enriched with Branched-Chain Amino Acids (BCAAs: leucine, isoleucine, valine; $35\%\text{--}45\%$) and depleted of Aromatic Amino Acids (AAAs: phenylalanine, tyrosine, tryptophan) and methionine. Based on the Fischer hypothesis, abnormal serum BCAA-to-AAA ratios allow aromatic amino acids to cross the blood-brain barrier and synthesize "false neurotransmitters" (octopamine, phenylethanolamine), worsening encephalopathy. In modern clinical practice, hepatic formulations are reserved exclusively for patients with severe, chronic hepatic encephalopathy refractory to first-line pharmacotherapy (lactulose and rifaximin). Standard amino acids are preferred in stable cirrhosis.
  • Renal Formulations (NephrAmine, Aminosyn RF): Formulated with essential amino acids only. Historically developed for non-dialyzed acute kidney injury to promote urea nitrogen recycling. Modern nephrology and critical care guidelines have rendered essential-only amino acid formulations largely obsolete; critically ill patients with AKI on continuous renal replacement therapy (CRRT) require standard balanced amino acid mixtures at high doses ($1.5\text{ to } 2.5\text{ g/kg/day}$) to replace dialysate amino acid clearance ($10\text{ to } 15\text{ g/day}$).
  • Pediatric/Neonatal Formulations (TrophAmine, Premasol): Calibrated for neonatal liver immaturity. Enriched with taurine, histidine, and tyrosine. Crucially, neonatal formulations require the addition of L-cysteine hydrochloride ($30\text{ to } 40\text{ mg}$ per gram of amino acids) immediately prior to compounding. Premature neonates have immature hepatic cystathionase activity, making cysteine an essential amino acid. Adding L-cysteine HCl also acidifies the solution pH, significantly enhancing calcium and phosphate solubility.

3. Intravenous Lipid Emulsions (IVLE)

Commercial lipid emulsions provide concentrated, non-protein calories and essential fatty acids:

• The Phospholipid-to-Triglyceride Ratio Paradox: Notice that $10\%$ and $20\%$ IVLE both contain the same amount of egg yolk phospholipid emulsifier ($12\text{ g/L}$). Consequently, a $10\%$ lipid emulsion delivers twice the amount of phospholipid per gram of triglyceride compared to a $20\%$ emulsion. This excess unesterified phospholipid binds circulating apolipoproteins and forms abnormal vesicular particles called Lipoprotein-X, which inhibits endothelial lipoprotein lipase (LPL). This delays plasma clearance of triglycerides, promoting hypertriglyceridemia and impaired reticuloendothelial clearance. Therefore, $20\%$ IVLE is clinically preferred over $10\%$ IVLE.

---

Lipid Generations & Oil Sources

EVOLUTION OF INTRAVENOUS LIPID EMULSIONS

1st GENERATION: 100% Soybean Oil (Intralipid)
  - High omega-6 PUFA (54% linoleic acid) -> Pro-inflammatory eicosanoids (PGE2, LTB4)
  - High phytosterols (stigmasterol) -> Impaired bile acid secretion -> PNALD / IFALD

MODERN MULTI-OIL: 4-Oil Blend (SMOFlipid)
  - 30% Soybean Oil: Essential linoleic and alpha-linolenic acids
  - 30% MCT (Coconut): Rapid carnitine-independent oxidation, no hepatic accumulation
  - 25% Olive Oil: Rich in oleic acid (MUFA), resistant to lipid peroxidation
  - 15% Fish Oil: Rich in EPA & DHA (omega-3), anti-inflammatory resoltins/protectins
  - Added alpha-tocopherol (vitamin E, ~200 mg/L) | Lower phytosterols | n-6:n-3 ratio ~2.5:1

TARGETED THERAPY: 100% Fish Oil (Omegaven)
  - Approved for pediatric patients to reverse Parenteral Nutrition-Associated Cholestasis (PNAC)

Clinical Lipid Monitoring and Ceilings

• Infusion Rate Limit: Intravenous lipid emulsion should be infused at a rate $\le 0.11\text{ g/kg/hour}$ to prevent reticuloendothelial saturation and hypertriglyceridemia.
• Dosing Range: General adult dosing is $1.0\text{ to } 1.5\text{ g/kg/day}$ (maximum $2.5\text{ g/kg/day}$). In critical illness, restricting lipid to $\le 1.0\text{ g/kg/day}$ or providing multi-oil formulations mitigates immunosuppression.
• Serum Triglyceride Monitoring: Obtain baseline serum triglycerides before initiating IVLE. Withhold or reduce IVLE if serum triglycerides exceed $400\text{ mg/dL}$ in adults (or $200\text{--}250\text{ mg/dL}$ in neonates) to prevent hypertriglyceridemia-induced acute pancreatitis.

---

Essential Fatty Acid Deficiency (EFAD)

Humans cannot synthesize carbon-carbon double bonds beyond the $\Delta^9$ position and depend on exogenous provision of two essential fatty acids:

1. Linoleic Acid (LA, 18:2n-6): Omega-6 polyunsaturated fatty acid.
2. Alpha-Linolenic Acid (ALA, 18:3n-3): Omega-3 polyunsaturated fatty acid.

Pathophysiology of EFAD

When a patient receives fat-free parenteral nutrition containing continuous high-dose dextrose, continuous insulin secretion suppresses adipose tissue lipolysis. Without exogenous linoleic acid, the intracellular enzyme $\Delta^6$-desaturase acts upon the abundant endogenous monounsaturated fatty acid oleic acid (18:1n-9). Oleic acid is elongated and desaturated into mead acid (5,8,11-eicosatrienoic acid, 20:3n-9), an abnormal triene:

NORMAL STATE (Adequate Linoleate): 
Linoleic Acid (18:2n-6) --------> Arachidonic Acid (20:4n-6, TETRAENE)

EFAD STATE (Dextrose suppression + Absence of Linoleate):
Oleic Acid (18:1n-9) -----------> Mead Acid (20:3n-9, TRIENE)

• The Holman Index: Biochemical EFAD is diagnosed using the triene-to-tetraene ratio (the ratio of mead acid to arachidonic acid). A triene-to-tetraene ratio $> 0.2$ confirms biochemical EFAD. Biochemical deficiency can develop within $7\text{ to } 14\text{ days}$ in infants and $1\text{ to } 3\text{ weeks}$ in adults receiving fat-free PN.
• Clinical Manifestations: Clinical symptoms appear after 2 to 4 weeks: dry, scaly erythematous dermatitis (ichthyosis-like desquamation, particularly in intertriginous areas), generalized alopecia, delayed wound healing, increased capillary fragility, thrombocytopenia, and increased susceptibility to infection.
• Prevention Requirements:
  • Supply $2\%\text{ to } 4\%$ of total daily calories as linoleic acid and $0.25\%\text{ to } 0.5\%$ as alpha-linolenic acid.
  • This requirement is satisfied by administering $250\text{ to } 500\text{ mL}$ of $20\%$ soybean oil IVLE once or twice weekly, or by incorporating daily multi-oil lipid emulsions ($1.0\text{ g/kg/day}$).

---

Glucose Infusion Rate (GIR)

The Glucose Infusion Rate (GIR) measures the rate at which intravenous carbohydrate is delivered to the circulation, normalized to body weight and time:

$\text{GIR (mg/kg/min)} = \frac{\text{Dextrose (grams)} \times 1000}{1440 \times \text{Weight (kg)}} = \frac{\text{Dextrose (grams)} \times 0.6944}{\text{Weight (kg)}}$

Where $1440$ is the total minutes in a 24-hour day ($24\text{ hr} \times 60\text{ min/hr} = 1440\text{ min}$). For a cyclic infusion infused over $H$ hours:

$\text{GIR}_{\text{cyclic}} = \frac{\text{Dextrose (grams)} \times 1000}{60 \times H \times \text{Weight (kg)}}$

Physiological Oxidation Ceilings

Consequences of Exceeding Maximum GIR

Administering dextrose beyond maximum physiological oxidation capacity produces severe metabolic toxicities:

1. Severe Hyperglycemia and Hyperosmolar Complications: Exceeding insulin-mediated transport results in severe hyperglycemia ($> 180\text{ mg/dL}$), glucosuria, osmotic diuresis, dehydration, loss of electrolytes (potassium, phosphate, magnesium), and increased risk of nosocomial infections.
2. Hepatic Steatosis: When glucose infusion exceeds the liver's oxidative capacity, excess carbohydrate is redirected into de novo lipogenesis, synthesizing palmitate and triglycerides. This leads to acute fat accumulation in hepatocytes (steatosis) and progressive elevation of transaminases and alkaline phosphatase.
3. Hypercapnia and Respiratory Compromise: De novo lipogenesis has a Respiratory Quotient (RQ) between $1.0\text{ and } 1.3$:

$\text{RQ} = \frac{V_{\text{CO}_2}}{V_{\text{O}_2}}$

Converting carbohydrate into fat releases substantial carbon dioxide ($V_{\text{CO}_2}$) relative to oxygen consumed ($V_{\text{O}_2}$). In mechanically ventilated patients or those with borderline pulmonary reserve (COPD, ARDS), the resulting hypercapnia dramatically increases minute ventilation demands and the work of breathing, precipitating respiratory acidosis and failure to wean from mechanical ventilation.